{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 25,
  "notes": "The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/31",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "OBJECTIVES: Selection of RP2D and MTD; Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ed2d070-ca75-42e6-b024-99f018676768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "list",
      "text": "PATIENT POPULATION: Advanced solid tumors harboring ROS1 fusions; ≥ 1 prior ROS1 TKI for NSCLC; No limit to prior therapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "497e76f1-2f7b-4f8e-aea4-48635ce9fc4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed August 2023: Updated data to be presented at a medical meeting in 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d3905a0-a5cc-49d4-9bc9-971dbfd56100",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.39,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; mg, milligram; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; QD, once daily; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdaa8e34-61c7-4942-b898-6b35ea2b4395",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.39,
        "y": 0.32
      },
      "kind": "table",
      "text": "NVL-520 Dose Cohorts table showing N=35 all-treated population and N=21 NSCLC response-evaluable population across 25mg, 50mg, 75mg, 100mg, 125mg QD doses.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "360b3e2b-641d-4af6-a1f8-9bac3ec4bdb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARROS-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ebd4d2d-19c1-4e69-8c3b-5890a761d2ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 17,
      "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents traction and clinical trial data from slides 17 to 36",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}